首页> 外文期刊>Cell metabolism >Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice.
【24h】

Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice.

机译:脂联素是糖尿病小鼠中PPARγ介导的内皮功能改善所必需的。

获取原文
获取原文并翻译 | 示例
           

摘要

Rosiglitazone is a PPARgamma agonist commonly used to treat diabetes. In addition to improving insulin sensitivity, rosiglitazone restores normal vascular function by a mechanism that remains poorly understood. Here we show that adiponectin is required to mediate the PPARgamma effect on vascular endothelium of diabetic mice. In db/db and diet-induced obese mice, PPARgamma activation by rosiglitazone restores endothelium-dependent relaxation of aortae, whereas diabetic mice lacking adiponectin or treated with an anti-adiponectin antibody do not respond. Rosiglitazone stimulates adiponectin release from fat explants, and subcutaneous fat transplantation from rosiglitazone-treated mice recapitulates vasodilatation in untreated db/db recipients. Mechanistically, adiponectin activates AMPK/eNOS and cAMP/PKA signaling pathways in aortae, which increase NO bioavailability and reduce oxidative stress. Taken together, these results demonstrate that adipocyte-derived adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetes. Thus, the adipose tissue represents a promising target for treating diabetic vasculopathy.
机译:罗格列酮是通常用于治疗糖尿病的PPARγ激动剂。除了提高胰岛素敏感性外,罗格列酮还通过一种尚不为人所知的机制恢复了正常的血管功能。在这里,我们显示脂联素是必需的,以介导PPARgamma对糖尿病小鼠血管内皮的作用。在db / db和饮食诱导的肥胖小鼠中,罗格列酮对PPARγ的激活可恢复主动脉的内皮依赖性舒张,而缺乏脂联素或经抗脂联素抗体治疗的糖尿病小鼠则无反应。罗格列酮刺激脂联素从脂肪外植体中释放,罗格列酮治疗小鼠的皮下脂肪移植在未经治疗的db / db受体中概括了血管舒张。从机理上讲,脂联素激活了主动脉中的AMPK / eNOS和cAMP / PKA信号通路,从而增加了NO的生物利用度并降低了氧化应激。综上所述,这些结果表明,脂肪细胞衍生的脂联素是PPARγ介导的糖尿病内皮功能改善所必需的。因此,脂肪组织代表了治疗糖尿病性血管病的有希望的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号